BRPI0917705A2 - composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto - Google Patents

composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto

Info

Publication number
BRPI0917705A2
BRPI0917705A2 BRPI0917705A BRPI0917705A BRPI0917705A2 BR PI0917705 A2 BRPI0917705 A2 BR PI0917705A2 BR PI0917705 A BRPI0917705 A BR PI0917705A BR PI0917705 A BRPI0917705 A BR PI0917705A BR PI0917705 A2 BRPI0917705 A2 BR PI0917705A2
Authority
BR
Brazil
Prior art keywords
compound
prodrug
disease
treating
preventing
Prior art date
Application number
BRPI0917705A
Other languages
English (en)
Portuguese (pt)
Inventor
Haruyuki Nishida
Ikuo Fujimori
Yasuyoshi Arikawa
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41508823&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0917705(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of BRPI0917705A2 publication Critical patent/BRPI0917705A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0917705A 2008-08-27 2009-08-26 composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto BRPI0917705A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008218851 2008-08-27
JP2008269099 2008-10-17
PCT/JP2009/065279 WO2010024451A1 (en) 2008-08-27 2009-08-26 Pyrrole compounds

Publications (1)

Publication Number Publication Date
BRPI0917705A2 true BRPI0917705A2 (pt) 2016-02-16

Family

ID=41508823

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0917705A BRPI0917705A2 (pt) 2008-08-27 2009-08-26 composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto

Country Status (38)

Country Link
US (3) US8969387B2 (enExample)
EP (1) EP2318390B1 (enExample)
JP (1) JP5638515B2 (enExample)
KR (1) KR101629181B1 (enExample)
CN (1) CN102197033B (enExample)
AR (1) AR073136A1 (enExample)
AU (1) AU2009284867B2 (enExample)
BR (1) BRPI0917705A2 (enExample)
CA (1) CA2735162C (enExample)
CL (1) CL2011000402A1 (enExample)
CO (1) CO6321166A2 (enExample)
CR (1) CR20110169A (enExample)
CY (1) CY1114452T1 (enExample)
DK (1) DK2318390T3 (enExample)
DO (1) DOP2011000061A (enExample)
EA (1) EA019741B1 (enExample)
EC (1) ECSP11010912A (enExample)
ES (1) ES2423289T3 (enExample)
GE (1) GEP20135786B (enExample)
HR (1) HRP20130653T1 (enExample)
IL (1) IL211335A (enExample)
JO (1) JO2871B1 (enExample)
MA (1) MA32647B1 (enExample)
ME (1) ME01598B (enExample)
MX (1) MX2011001955A (enExample)
MY (1) MY152008A (enExample)
NZ (1) NZ591793A (enExample)
PE (2) PE20110300A1 (enExample)
PL (1) PL2318390T3 (enExample)
PT (1) PT2318390E (enExample)
RS (1) RS52872B (enExample)
SI (1) SI2318390T1 (enExample)
SM (1) SMT201300085B (enExample)
TW (1) TWI473798B (enExample)
UA (1) UA105185C2 (enExample)
UY (1) UY32074A (enExample)
WO (1) WO2010024451A1 (enExample)
ZA (1) ZA201101774B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101629181B1 (ko) * 2008-08-27 2016-06-13 다케다 야쿠힌 고교 가부시키가이샤 피롤 화합물
US20110229879A1 (en) * 2010-03-19 2011-09-22 University Of Rochester Methods and compositions for nuclear staining
CN102452979B (zh) * 2010-11-03 2015-04-01 天津药明康德新药开发有限公司 5-氟-3-吡啶磺酰氯的合成方法
CN102863371B (zh) * 2011-07-06 2016-04-13 中国科学院上海有机化学研究所 氟代二氢吡咯或氟代吡咯
US10039813B2 (en) 2012-02-07 2018-08-07 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
TWI623327B (zh) 2012-06-27 2018-05-11 武田藥品工業股份有限公司 液狀製劑
US9487485B2 (en) 2013-02-28 2016-11-08 Takeda Pharmaceutical Company Limited Method for producing sulfonyl chloride compound
US9724396B2 (en) 2013-03-15 2017-08-08 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
KR102084185B1 (ko) 2013-08-29 2020-03-04 주식회사 대웅제약 테트라히드로사이클로펜타피롤 유도체 및 이의 제조방법
CN105367550A (zh) * 2014-08-11 2016-03-02 江苏柯菲平医药股份有限公司 四氢环戊二烯并[c]吡咯类衍生物、其制备方法及其在医药上的应用
UY36547A (es) 2015-02-05 2016-06-01 Bayer Cropscience Ag Derivados heterocíclicos condensados bicíclicos sustituidos por 2-(het)arilo como pesticidas
WO2016138099A1 (en) 2015-02-24 2016-09-01 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
BR112018001859B1 (pt) 2015-07-30 2023-05-02 Takeda Pharmaceutical Company Limited Comprimido, e, método para produzir um comprimido
CA2994604A1 (en) 2015-08-07 2017-02-16 Bayer Cropscience Aktiengesellschaft 2-(het)aryl-substituted condensed heterocyclic derivatives as pest control agents
CN106430006B (zh) * 2016-08-18 2018-06-12 国网湖南省电力公司带电作业中心 配电线路移动式绝缘登高作业装置及方法
CN108203430A (zh) * 2016-12-16 2018-06-26 天地人和生物科技有限公司 一种新型可逆性质子泵抑制剂及其制备方法和用途
BR112020000318A2 (pt) 2017-07-10 2020-07-14 Takeda Pharmaceutical Company Limited preparação
KR102126576B1 (ko) 2018-09-19 2020-06-24 주식회사 대웅제약 4-메톡시 피롤 유도체의 제조 방법
CN113527536B (zh) * 2020-04-21 2024-03-22 杭州德柯医疗科技有限公司 一种含氟多糖高分子化合物及其制备方法
HUE070031T2 (hu) * 2020-06-17 2025-05-28 Ildong Pharmaceutical Co Ltd Új savszekréciós inhibitor és alkalmazása
EP4074317A1 (en) 2021-04-14 2022-10-19 Bayer AG Phosphorus derivatives as novel sos1 inhibitors
CN113620930B (zh) * 2021-07-12 2022-08-16 南京烁慧医药科技有限公司 一种含磺酰胺结构的化合物及其制备方法和应用、一种药物组合物及应用
KR20240119083A (ko) * 2021-12-15 2024-08-06 일동제약(주) 1-설포닐 피롤 유도체의 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물
US20250084026A1 (en) * 2021-12-15 2025-03-13 Ildong Pharmaceutical Co., Ltd. Novel salt of 1-sulfonyl pyrrole derivative, preparation method thereof and pharmaceutical composition comprising thereof
KR20230102353A (ko) * 2021-12-30 2023-07-07 주식회사 대웅제약 삼중음성유방암의 예방 또는 치료용 약학적 조성물

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE66477T1 (de) 1986-08-29 1991-09-15 Pfizer 2-guanidino-4-aryl-thiazole fuer die behandlung von peptischen geschwueren.
US5128366A (en) 1990-07-05 1992-07-07 Shinogi & Co., Ltd. Pyrrole derivatives
US5331006A (en) 1990-08-31 1994-07-19 Warner-Lambert Company Amino acid analogs as CCK antagonists
WO1992004025A1 (en) 1990-08-31 1992-03-19 Warner-Lambert Company Amino acid analogs as cck antagonists
AU664392B2 (en) 1991-10-18 1995-11-16 Monsanto Technology Llc Fungicides for the control of take-all disease of plants
MX9205392A (es) 1991-10-29 1993-04-01 Du Pont Triazolcarbozamidas herbicidas y procedimiento para su obtencion.
JPH06135961A (ja) 1992-10-23 1994-05-17 Nippon Iyakuhin Kogyo Kk 新規ジフェニルピロリルフラン誘導体
US5286742A (en) 1992-11-03 1994-02-15 American Cyanamid Company Pyrrole thiocarboxamide insecticidal and acaricidal agents
US5480902A (en) 1993-08-31 1996-01-02 American Cyanamid Company Thienylpyrrole fungicidal agents
JPH08119936A (ja) 1994-10-18 1996-05-14 Fujisawa Pharmaceut Co Ltd 複素環式誘導体
JPH0930967A (ja) 1995-07-17 1997-02-04 Chugai Pharmaceut Co Ltd 抗潰瘍剤
SK25099A3 (en) 1996-08-28 2000-02-14 Procter & Gamble Substituted cyclic amine metalloprotease inhibitors
EP0946508B1 (en) 1996-12-23 2009-09-23 Bristol-Myers Squibb Pharma Company NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS
JPH11209344A (ja) 1998-01-26 1999-08-03 Kyowa Hakko Kogyo Co Ltd 含窒素複素環化合物
GB9817548D0 (en) 1998-08-12 1998-10-07 Novartis Ag Organic compounds
WO2000053573A1 (en) 1999-03-10 2000-09-14 Shionogi & Co., Ltd. Medicinal compositions with [2.2.1] and [3.1.1] bicycloskeleton antagonistic to both of pgd2/txa2 receptors
TW575561B (en) 1999-03-25 2004-02-11 Hoffmann La Roche 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives
AU3783100A (en) 1999-06-14 2000-12-21 Dow Agrosciences Llc Substituted triazoles, imidazoles and pyrazoles as herbicides
WO2001014358A2 (en) 1999-08-26 2001-03-01 Aventis Pharmaceuticals Inc. Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benozopyrans
US6911468B2 (en) 2000-05-22 2005-06-28 Takeda Chemical Industries, Ltd. Tyrosine phosphatase inhibitors
US6589978B2 (en) 2000-06-30 2003-07-08 Hoffman-La Roche Inc. 1-sulfonyl pyrrolidine derivatives
GB0016453D0 (en) 2000-07-04 2000-08-23 Hoffmann La Roche Pyrrole derivatives
WO2003028641A2 (en) 2001-10-01 2003-04-10 Taisho Pharmaceutical Co., Ltd. Mch receptor antagonists
US6919359B2 (en) 2001-11-08 2005-07-19 Pfizer Inc Azabicyclic-substituted-heteroaryl compounds for the treatment of disease
AU2002342909A1 (en) 2001-11-22 2003-06-10 Ciba Specialty Chemicals Holding Inc. Pyrrole synthesis
US20050101657A1 (en) 2001-12-28 2005-05-12 Takeda Chemical Industries Ltd. Androgen receptor antagonists
AU2003216274A1 (en) 2002-02-11 2003-09-04 Neurocrine Biosciences, Inc. Pyrrole derivatives as ligands of melanocortin receptors
AU2003209114A1 (en) 2002-02-14 2003-09-04 Wyeth Pyrrolylalkylidene-hydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands
TW200306191A (en) 2002-02-22 2003-11-16 Teijin Ltd Pyrrolopyrimidine derivatives
JP4287816B2 (ja) 2002-06-13 2009-07-01 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー ピラゾールカルボキサミド殺虫剤
BR0313396A (pt) 2002-08-12 2005-06-28 Sugen Inc 3-pirrolil-piridopirazóis e 3-pirrolil-indazóis, como inibidores de quinase
JP2004315511A (ja) 2003-03-31 2004-11-11 Taisho Pharmaceut Co Ltd Ｍｃｈ受容体アンタゴニスト
ES2351393T3 (es) 2003-05-26 2011-02-03 Takeda Pharmaceutical Company Limited Sulfopirroles.
US8048909B2 (en) 2004-09-30 2011-11-01 Takeda Pharmaceutical Company Limited Proton pump inhibitors
EP1655284A1 (en) 2004-10-26 2006-05-10 Aponetics AG 2-Phenylsulfopyrroles
US7977488B2 (en) 2005-08-30 2011-07-12 Takeda Pharmaceutical Company Limited 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors
US8512761B2 (en) 2006-01-27 2013-08-20 Yale University Fast acting inhibitor of gastric acid secretion
US7994205B2 (en) 2006-03-31 2011-08-09 Takeda Pharmaceutical Company Limited Aryl-or heteroaryl-sulfonyl compounds as acid secretion inhibitors
US8933105B2 (en) * 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
US20090156642A1 (en) 2007-09-28 2009-06-18 Takeda Pharmaceutical Company Limited 5-Membered heterocyclic compound
US20090318429A1 (en) 2008-04-28 2009-12-24 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives
WO2009140624A2 (en) 2008-05-16 2009-11-19 Takeda San Diego, Inc. Glucokinase activators
KR101629181B1 (ko) 2008-08-27 2016-06-13 다케다 야쿠힌 고교 가부시키가이샤 피롤 화합물

Also Published As

Publication number Publication date
IL211335A0 (en) 2011-04-28
EA201170384A1 (ru) 2011-10-31
CN102197033A (zh) 2011-09-21
US8993598B2 (en) 2015-03-31
EP2318390A1 (en) 2011-05-11
ME01598B (me) 2014-09-20
CY1114452T1 (el) 2016-10-05
EA019741B1 (ru) 2014-05-30
CA2735162A1 (en) 2010-03-04
ZA201101774B (en) 2012-06-27
TWI473798B (zh) 2015-02-21
UY32074A (es) 2010-03-26
NZ591793A (en) 2012-11-30
AU2009284867A1 (en) 2010-03-04
SI2318390T1 (sl) 2013-08-30
US20140031393A1 (en) 2014-01-30
PT2318390E (pt) 2013-07-10
AR073136A1 (es) 2010-10-13
CL2011000402A1 (es) 2011-07-29
PE20110300A1 (es) 2011-06-16
PE20141174A1 (es) 2014-09-19
KR101629181B1 (ko) 2016-06-13
CN102197033B (zh) 2014-07-16
MY152008A (en) 2014-08-15
HRP20130653T1 (en) 2013-08-31
IL211335A (en) 2013-12-31
CO6321166A2 (es) 2011-09-20
US20110172275A1 (en) 2011-07-14
ECSP11010912A (es) 2011-04-29
DOP2011000061A (es) 2011-04-15
MA32647B1 (fr) 2011-09-01
CA2735162C (en) 2015-06-23
ES2423289T3 (es) 2013-09-19
SMT201300085B (it) 2013-09-06
WO2010024451A1 (en) 2010-03-04
KR20110071067A (ko) 2011-06-28
DK2318390T3 (da) 2013-07-08
RS52872B (sr) 2013-12-31
US8969387B2 (en) 2015-03-03
AU2009284867A2 (en) 2011-04-21
PL2318390T3 (pl) 2013-09-30
JP5638515B2 (ja) 2014-12-10
HK1157756A1 (en) 2012-07-06
US20100056577A1 (en) 2010-03-04
UA105185C2 (uk) 2014-04-25
MX2011001955A (es) 2011-03-29
EP2318390B1 (en) 2013-05-01
US8592597B2 (en) 2013-11-26
TW201010993A (en) 2010-03-16
JP2012501296A (ja) 2012-01-19
AU2009284867B2 (en) 2014-08-28
JO2871B1 (en) 2015-03-15
GEP20135786B (en) 2013-03-11
CR20110169A (es) 2011-05-16

Similar Documents

Publication Publication Date Title
BRPI0917705A2 (pt) composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto
BRPI0917458A2 (pt) composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
BRPI0819755A2 (pt) composto, composição farmacêutica, processos para a preparação de um composto e de uma composição farmacêutica, uso de um composto, e, método para tratar ou reduzir o risco de uma doença ou uma condição inflamatória
BRPI0819799A2 (pt) Composto, intermediário, uso de um composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença
BRPI0907977A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0818244A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BRPI1013984A2 (pt) composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto.
BRPI0913585A2 (pt) composto, método para fabricar um composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios
BRPI0815591A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença, condição ou distúrbio.
BRPI0915084A2 (pt) composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, métodos para a profilaxia ou tratamento de um estado de doença ou uma condição e de câncer
BRPI0907974A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI1008383A2 (pt) composto, composição farmacêutica, método para prevenir, inibir ou tratar uma condição, e, uso de um composto
BRPI0821299A2 (pt) Composto, processo para preparar o mesmo, composição farmacêutica, processo para preparar a mesma, uso de um composto, e, método para tratar, ou reduzir o risco de, uma doença ou condição.
BRPI0819218A2 (pt) Métodos, estojos e composições para administração de compostos farmacêuticos
BRPI0911685A2 (pt) composto, método para o tratamento de uma doença, uso de um composto, composição farmacêutica, e, kit
BRPI0917138A2 (pt) composto, métodos para tratar doenças alérgicas e outras condições inflamatórias, rinite alérgica, e para tratar ou prevenir doença, composição farmacêutica, uso de um composto, e, combinação.
BRPI0822398A2 (pt) Forma sólida, mistura, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou distúrbio e um câncer
BRPI0912348A2 (pt) composto de 3-aminocarbazol, composição farmacêutica, método para preparar um composto de 3-aminocarbazol, uso de um composto de 3-aminocarbazol, e, método para tratar ou prevenir doenças
BRPI0909768A2 (pt) composto, composição farmacêutica, método para o tratamento ou prevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto""composto, composição farmacêutica, método para o tratamento ou orevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto
BRPI0915382A2 (pt) composto, composição farmacêutica, e, método para tratar uma doença ou um distúrbio.
BR112012016398A2 (pt) Composto imidazopiridinil-aminopiridino substituído, composição farmacêutica que compreende o referido composto e uso do mesmo para o tratamento de uma doença celular proliferativa
BR112014011671A2 (pt) composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto
BR112012004333A2 (pt) composto, composição farmacêutica, e, método para o tratamento ou a prevenção de uma doença ou um distúrbio.
BRPI0816881A2 (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]